


## CLAIMS

1. A compound of Formula (I):



or a pharmaceutically acceptable salt thereof, wherein:

Q is 1,2,4-triazin-3-yl, pyridazin-3-yl, 6-methylpyridazin-3-yl, or 6-fluoropyridazin-3-yl;  
 $R^1$  is hydrogen, methoxy, trifluoromethoxy, oxetan-3-yl, 3-fluoroazetidin-1-yl, 3-methoxyazetidin-1-yl, or 3,3-difluoroazetidin-1-yl;  
 $R^2$  is hydrogen or fluoro;  
 $R^3$  is hydrogen or methoxy; and  
 $R^4$  is methoxy, ethoxy, or methoxymethyl;  
 provided that when  $R^1$  is hydrogen, methoxy or trifluoromethoxy, then  $R^3$  is not hydrogen, and/or  $R^4$  is methoxymethyl.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein  $R^1$  is methoxy and  $R^3$  is methoxy.

3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein  $R^1$  is oxetan-3-yl, 3-fluoroazetidin-1-yl; 3-methoxyazetidin-1-yl, or 3,3-difluoroazetidin-1-yl.

4. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein  $R^2$  is H.

5. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt thereof, wherein  $R^3$  is methoxy.

6. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein R<sup>4</sup> is methoxy.

7. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt thereof, wherein Q is 1,2,4-triazin-3-yl, or pyridazin-3-yl.

8. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:

(2S)-2-[3-(3-fluoroazetidin-1-yl)phenyl]-2-methoxy-N-[5-[[[(3R)-1-pyridazin-3-ylpyrrolidin-3-yl]amino]-1,3,4-thiadiazol-2-yl]acetamide;

(2S)-2-(3,5-dimethoxyphenyl)-2-methoxy-N-[5-[[[(3R)-1-(6-methylpyridazin-3-yl)pyrrolidin-3-yl]amino]-1,3,4-thiadiazol-2-yl]acetamide;

(2S)-2-[3-(3,3-difluoroazetidin-1-yl)phenyl]-2-methoxy-N-[5-[[[(3R)-1-pyridazin-3-ylpyrrolidin-3-yl]amino]-1,3,4-thiadiazol-2-yl]acetamide;

(2S)-2-methoxy-2-[3-(3-methoxyazetidin-1-yl)phenyl]-N-[5-[[[(3R)-1-pyridazin-3-ylpyrrolidin-3-yl]amino]-1,3,4-thiadiazol-2-yl]acetamide;

(2S)-2-(3,5-dimethoxyphenyl)-2-methoxy-N-[5-[[[(3R)-1-(1,2,4-triazin-3-yl)pyrrolidin-3-yl]amino]-1,3,4-thiadiazol-2-yl]acetamide;

(2R)-3-methoxy-2-(3-methoxyphenyl)-N-[5-[[[(3R)-1-pyridazin-3-ylpyrrolidin-3-yl]amino]-1,3,4-thiadiazol-2-yl]propanamide;

(2S)-2-(3,5-dimethoxyphenyl)-2-ethoxy-N-[5-[[[(3R)-1-pyridazin-3-ylpyrrolidin-3-yl]amino]-1,3,4-thiadiazol-2-yl]acetamide;

(2S)-2-[4-fluoro-3-(3-methoxyazetidin-1-yl)phenyl]-2-methoxy-N-[5-[(3R)-3-(pyridazin-3-ylamino)pyrrolidin-1-yl]-1,3,4-thiadiazol-2-yl]acetamide;

(2S)-N-[5-[[[(3R)-1-(6-fluoropyridazin-3-yl)pyrrolidin-3-yl]amino]-1,3,4-thiadiazol-2-yl]-2-methoxy-2-[3-(3-methoxyazetidin-1-yl)phenyl]acetamide;

(2S)-2-[3-(3-fluoroazetidin-1-yl)-5-methoxy-phenyl]-2-methoxy-N-[5-[[[(3R)-1-pyridazin-3-ylpyrrolidin-3-yl]amino]-1,3,4-thiadiazol-2-yl]acetamide;

(2S)-2-methoxy-2-[3-methoxy-5-(trifluoromethoxy)phenyl]-N-[5-[[[(3R)-1-pyridazin-3-ylpyrrolidin-3-yl]amino]-1,3,4-thiadiazol-2-yl]acetamide;

(2R)-2-methoxy-2-[3-methoxy-5-(trifluoromethoxy)phenyl]-N-[5-[(3R)-1-pyridazin-3-ylpyrrolidin-3-yl]amino]-1,3,4-thiadiazol-2-yl]acetamide;

(2S)-2-(4-fluorophenyl)-2-methoxy-N-[5-[(3R)-1-(5-methylpyridazin-3-yl)pyrrolidin-3-yl]amino]-1,3,4-thiadiazol-2-yl]acetamide;

(2S)-2-methoxy-2-[3-(3-methoxyazetidin-1-yl)phenyl]-N-[5-[(3R)-1-(6-methylpyridazin-3-yl)pyrrolidin-3-yl]amino]-1,3,4-thiadiazol-2-yl]acetamide;

(2S)-2-[4-fluoro-3-(3-fluoroazetidin-1-yl)phenyl]-2-methoxy-N-[5-[(3R)-1-pyridazin-3-ylpyrrolidin-3-yl]amino]-1,3,4-thiadiazol-2-yl]acetamide;

(2S)-2-[3-(3,3-difluoroazetidin-1-yl)phenyl]-2-methoxy-N-[5-[(3R)-1-(1,2,4-triazin-3-yl)pyrrolidin-3-yl]amino]-1,3,4-thiadiazol-2-yl]acetamide;

(2S)-2-methoxy-2-[3-(3-methoxyazetidin-1-yl)phenyl]-N-[5-[(3R)-1-(1,2,4-triazin-3-yl)pyrrolidin-3-yl]amino]-1,3,4-thiadiazol-2-yl]acetamide;

(2S)-2-[3-(3-fluoroazetidin-1-yl)phenyl]-2-methoxy-N-[5-[(3R)-1-(1,2,4-triazin-3-yl)pyrrolidin-3-yl]amino]-1,3,4-thiadiazol-2-yl]acetamide; and

(2S)-2-methoxy-2-[3-(oxetan-3-yl)phenyl]-N-[5-[(3R)-1-pyridazin-3-ylpyrrolidin-3-yl]amino]-1,3,4-thiadiazol-2-yl]acetamide.

9. A compound, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:

(2S)-2-ethoxy-N-[5-[(3R)-1-pyridazin-3-ylpyrrolidin-3-yl]amino]-1,3,4-thiadiazol-2-yl]-2-[3-(trifluoromethoxy)phenyl]acetamide;

(2R)-2-[4-fluoro-3-(trifluoromethoxy)phenyl]-2-methoxy-N-[5-[(3R)-1-pyridazin-3-ylpyrrolidin-3-yl]amino]-1,3,4-thiadiazol-2-yl]acetamide;

(2S)-2-[4-fluoro-3-(trifluoromethoxy)phenyl]-2-methoxy-N-[5-[(3R)-1-pyridazin-3-ylpyrrolidin-3-yl]amino]-1,3,4-thiadiazol-2-yl]acetamide; and

(2S)-[3-(difluoromethoxy)phenyl]-2-ethoxy-N-[5-[(3R)-1-pyridazin-3-ylpyrrolidin-3-yl]amino]-1,3,4-thiadiazol-2-yl]acetamide.

10. A pharmaceutical composition comprising the compound of any one of claims 1-9, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable diluent or carrier.

11. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt thereof, for use in therapy.

12. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer.

13. The use of the compound of any one of claims 1-9, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of cancer.

14. The compound for use according to claim 12, wherein the cancer is breast cancer, lung cancer, pancreatic cancer, renal cancer, or hepatocellular cancer.

15. The use according to claim 13, wherein the cancer is breast cancer, lung cancer, pancreatic cancer, renal cancer, or hepatocellular cancer.